Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Additional Reports of Exempt Distribution

No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Additional Reports of Exempt Distribution

KOO-KOO2

Jul 05, 2023 06:22AM

Re: Additional Reports of Exempt Distribution

KOO-KOO2

Jul 22, 2023 07:01AM

Re: Additional Reports of Exempt Distribution

Nextblockbuster

Jul 22, 2023 07:54AM

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Additional Reports of Exempt Distribution

in response to

Re: Additional Reports of Exempt Distribution

Nextblockbuster

posted on Jul 22, 2023 11:48AM

As I see it, they buy new shares directly from the company because they don't trust the OTC.

Less trade liquidity in acquiring shares in the 10's of thousands of shares on the OTC.

Don the salesman may have something to do with it!

Koo (IMO)

1 Recommendations

Re: Additional Reports of Exempt Distribution

Toinv

Jul 24, 2023 05:11PM

Re: Additional Reports of Exempt Distribution

tada

Jul 25, 2023 02:48AM